About: PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY
Creator	Eilami, Owrang Fathi, Mobina Hajiesmaeili, Mohammadreza Mohamadkhani, Ashraf Rezaei-Tavirani, Mostafa Sayehmiri, Fatemeh Vakili, Kimia
Source	MedRxiv
abstract	Abstract: Background and Aim: With the increase in the number of COVID-19 infections, global health is facing insufficient sources; this study aimed to provide additional data regarding the clinical characteristics of patients diagnosed with COVID-19 and in particular to analyze the factors associated with disease severity, unimprovement and mortality. Methods: 82 studies were included in the present meta-analysis that all of them have been published before May 1, 2020 and were found by searching through the databases Scopus and MEDLINE. The selected papers were studied and analyzed by employing the version 14 of stata software. It should be noted that, we employed I2 statistics for testing and verifying heterogeneity. Results: 82 papers were finally chosen for this meta- analysis, including 74855 infected patients (35673 men, 31140 women). The mean age of the patients was 56.49. The results indicate the prevalence of fever 79.84 (95% CI: 75.22-84.13), cough 59.53 (95% CI: 55.35-63.65), fatigue or myalgia 33.46 (95% CI: 28.68-38.40), dyspnea 31.48 (95% CI: 25.75-37.49) and diarrhea 10.71 (95% CI: 8.20-13.49). The prevalence of the most common comorbidities were hypertension 25.10 (95% CI: 19.91-30.64), diabetes 13.48 (95% CI: 10.61-16.62), cardiovascular diseases 8.94 (95% CI: 6.99-11.10), and chronic kidney disease 3.27 (95% CI: 2.22-4.47). Conclusion: The results of this study are seriously needed to effectively monitor the health of people with comorbidities (hypertension, diabetes, cardiovascular and cerebrovascular disease, coronary heart disease, and chronic kidney disease) to prevent the development of COVID-19 infection.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.11.20128835
has license	medrxiv
sha1sum (hex)	9d494df17bf19f1d086577d62f65b4f80409dcf5
schema:url	https://doi.org/10.1101/2020.06.11.20128835
resource representing a document's title	PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY
resource representing a document's body	covid:9d494df17bf19f1d086577d62f65b4f80409dcf5#body_text
is schema:about of	named entity 'META-ANALYSIS STUDY' named entity 'preprint' named entity 'copyright holder' named entity 'preprint' named entity 'preprint' named entity 'peer review' named entity 'preprint' named entity 'medRxiv' named entity 'peer review' named entity 'doi' named entity 'medRxiv' named entity 'preprint' named entity 'peer review' named entity 'peer review' named entity 'copyright holder' named entity 'preprint' named entity 'medRxiv' named entity 'medRxiv' named entity 'PROGNOSTIC' named entity 'peer review' named entity 'medRxiv' named entity 'copyright holder' named entity 'preprint' named entity 'SYSTEMATIC REVIEW' named entity 'COVID-19' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'copyright holder' named entity 'peer review' named entity 'peer review' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'peer review' named entity 'copyright holder' named entity 'copyright holder' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'copyright holder' named entity 'copyright holder' named entity 'copyright holder' named entity 'peer review' named entity 'medRxiv' named entity 'peer review' named entity 'preprint' named entity 'copyright holder' named entity 'copyright holder' named entity 'preprint' named entity 'J P' named entity 'medRxiv' named entity 'medRxiv' named entity 'medRxiv' named entity 'copyright holder' named entity 'preprint' named entity 'peer review' named entity 'medRxiv' named entity 'preprint' named entity '10.1101' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'peer review' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'peer review' named entity 'copyright holder' named entity 'preprint' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software